Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells

Nature Communications

Volumn 8, Issue , 2017, Pages

  Pan, Feng ^a,b,c   Wingo, Thomas S ^d,e   Zhao, Zhigang ^f   Gao, Rui ^a   Makishima, Hideki ^g   Qu, Guangbo ^a,b   Lin, Li ^d   Yu, Miao ^h   Ortega, Janice R ⁱ   Wang, Jiapeng ^b   Nazha, Aziz ^g   Chen, Li ^d   Yao, Bing ^d   Liu, Can ^a   Chen, Shi ^a   Weeks, Ophelia ^c   Ni, Hongyu ^j   Phillips, Brittany Lynn ^d   Huang, Suming ^k   Wang, Jianlong ^l   He, Chuan ^h   Li, Guo Min ⁱ   Radivoyevitch, Tomas ^g   Aifantis, Iannis ^m,n   MacIejewski, Jaroslaw P ^g   Yang, Feng Chun ^a,b   Jin, Peng ^d   Xu, Mingjiang ^a,b   more..

^a UNIVERSITY OF MIAMI   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f TIANJIN MEDICAL UNIVERSITY   (China)

^g TAUSSIG CANCER INSTITUTE   (United States)

^h UNIVERSITY OF CHICAGO   (United States)

ⁱ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^j UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^k UNIVERSITY OF FLORIDA   (United States)

^l MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^m NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; CBL PROTEIN; CD4 ANTIGEN; CD45 ANTIGEN; CD5 ANTIGEN; CD8 ANTIGEN; DIOXYGENASE; FLT3 LIGAND; HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; IMMUNOGLOBULIN M; LIN PROTEIN; MLL2 PROTEIN; NF1 PROTEIN; NOTCH1 RECEPTOR; PROTEIN; STEM CELL FACTOR; T LYMPHOCYTE RECEPTOR; TET2 PROTEIN; UNCLASSIFIED DRUG; 5 METHYLCYTOSINE; 5-HYDROXYMETHYLCYTOSINE; DNA BINDING PROTEIN; ONCOPROTEIN; SMALL INTERFERING RNA; TET2 PROTEIN, HUMAN; TET2 PROTEIN, MOUSE;

CANCER; CATALYSIS; CATALYST; CELLS AND CELL COMPONENTS; ENZYME; ENZYME ACTIVITY; HEMATOLOGY; MUTATION; ORGANIC COMPOUND; OXIDATION; PHYSIOLOGY;

5' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME DELETION; COHORT ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DNA REPLICATION; EXON; FLOW CYTOMETRY; GENE OVEREXPRESSION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HEPATOSPLENOMEGALY; HUMAN; HUMAN CELL; HYPERMUTAGENICITY; LEUKOCYTE COUNT; LYMPH NODE; LYMPHADENOPATHY; LYMPHOCYTIC INFILTRATION; LYMPHOCYTOSIS; MOUSE; MUTAGENICITY; MUTATION RATE; NONHUMAN; OXIDATION; PATHOGENESIS; SANGER SEQUENCING; SINGLE CELL ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; SPLEEN CELL; SPLENOMEGALY; STEM CELL SELF-RENEWAL; THYMUS DISEASE; WHOLE EXOME SEQUENCING; WILD TYPE; AGED; ANALOGS AND DERIVATIVES; ANIMAL; DNA DEMETHYLATION; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HEMATOLOGIC DISEASE; KNOCKOUT MOUSE; METABOLISM; MORTALITY; MUTAGENESIS; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

MUS;

5-METHYLCYTOSINE; AGED; ANIMALS; CELL LINE, TUMOR; DNA DEMETHYLATION; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELLS; HUMANS; MICE; MICE, KNOCKOUT; MUTAGENESIS; MUTATION RATE; PROTO-ONCOGENE PROTEINS; RNA, SMALL INTERFERING; SINGLE-CELL ANALYSIS; WHOLE EXOME SEQUENCING;

EID: 85028922056     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms15102     Document Type: Article

References (46)

1. He, Y. F. et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 333, 1303-1307 (2011).
2. Ito, S. et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 333, 1300-1303 (2011).
3. Tahiliani, M. et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324, 930-935 (2009).
4. Kohli, R. M. & Zhang, Y. TET enzymes, TDG and the dynamics of DNA demethylation. Nature 502, 472-479 (2013).
5. Wu, S. C. & Zhang, Y. Active DNA demethylation: many roads lead to Rome. Nat. Rev. Mol. Cell Biol. 11, 607-620 (2010).
6. Delhommeau, F. et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 360, 2289-2301 (2009).
7. Langemeijer, S. M. et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat. Genet. 41, 838-842 (2009).
8. Tefferi, A. et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 23, 905-911 (2009).
9. Jankowska, A. M. et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 113, 6403-6410 (2009).
10. Couronne, L., Bastard, C. & Bernard, O. A. TET2 and DNMT3A mutations in human T-cell lymphoma. N. Engl. J. Med. 366, 95-96 (2012).
11. Asmar, F. et al. Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma. Haematologica 98, 1912-1920 (2013).
12. Meissner, B. et al. The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma. Blood 121, 3161-3164 (2013).
13. Busque, L. et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat. Genet. 44, 1179-1181 (2012).
14. Li, Z. et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 118, 4509-4518 (2011).
15. Moran-Crusio, K. et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 20, 11-24 (2011).
16. Quivoron, C. et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20, 25-38 (2011).
17. Zhao, Z. et al. Combined loss of Tet1 and Tet2 promotes B cell, but not myeloid malignancies, in mice. Cell Rep. 13, 1692-1704 (2015).
18. Ko, M. et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468, 839-843 (2010).
19. Zhao, Z. et al. The catalytic activity of TET2 is essential for its myeloid malignancy-suppressive function in hematopoietic stem/progenitor cells. Leukemia 30, 1784-1788 (2016).
20. Brecqueville, M. et al. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes Cancer 51, 743-755 (2012).
21. Holmfeldt, L. et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat. Genet. 45, 242-252 (2013).
22. Patel, J. P. et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N. Engl. J. Med. 366, 1079-1089 (2012).
23. Paulsson, K. et al. Microdeletions are a general feature of adult and adolescent acute lymphoblastic leukemia: Unexpected similarities with pediatric disease. Proc. Natl Acad. Sci. USA 105, 6708-6713 (2008).
24. Weng, A. P. et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306, 269-271 (2004).
25. Song, C. X. et al. Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat. Biotechnol. 29, 68-72 (2011).
26. Huang, Y. et al. Distinct roles of the methylcytosine oxidases Tet1 and Tet2 in mouse embryonic stem cells. Proc. Natl Acad. Sci. USA 111, 1361-1366 (2014).
27. Laird, C. D. et al. Hairpin-bisulfite PCR: assessing epigenetic methylation patterns on complementary strands of individual DNA molecules. Proc. Natl Acad. Sci. USA 101, 204-209 (2004).
28. Bird, A. DNA methylation patterns and epigenetic memory. Genes Dev. 16, 6-21 (2002).
29. Maiti, A. & Drohat, A. C. Thymine DNA glycosylase can rapidly excise 5-formylcytosine and 5-carboxylcytosine: potential implications for active demethylation of CpG sites. J. Biol. Chem. 286, 35334-35338 (2011).
30. Weber, A. R. et al. Biochemical reconstitution of TET1-TDG-BER-dependent active DNA demethylation reveals a highly coordinated mechanism. Nat. Commun. 7, 10806 (2016).
31. Rideout, III W. M., Coetzee, G. A., Olumi, A. F. & Jones, P. A. 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science 249, 1288-1290 (1990).
32. Shibutani, T. et al. Guanine-5-carboxylcytosine base pairs mimic mismatches during DNA replication. Scientific Rep. 4, 5220 (2014).
33. Nilsen, H. et al. Gene-targeted mice lacking the Ung uracil-DNA glycosylase develop B-cell lymphomas. Oncogene 22, 5381-5386 (2003).
34. Wong, E. et al. Mbd4 inactivation increases Cright-arrowT transition mutations and promotes gastrointestinal tumor formation. Proc. Natl Acad Sci. USA 99, 14937-14942 (2002).
35. Song, C. X. et al. Genome-wide profiling of 5-formylcytosine reveals its roles in epigenetic priming. Cell 153, 678-691 (2013).
36. Lu, X. et al. Base-resolution maps of 5-formylcytosine and 5-carboxylcytosine reveal genome-wide DNA demethylation dynamics. Cell Res. 25, 386-389 (2015).
37. Wu, H. & Zhang, Y. Charting oxidized methylcytosines at base resolution. Nat. Struct. Mol. Biol. 22, 656-661 (2015).
38. Xiong, J. et al. Cooperative action between SALL4A and TET proteins in stepwise oxidation of 5-methylcytosine. Mol. Cell 64, 913-925 (2016).
39. Johnston, H. R. et al. PEMapper and PECaller provide a simplified approach to whole-genome sequencing. Proc. Natl Acad. Sci. USA 114, E1923-E1932 (2017).
40. Shetty, A. C. et al. SeqAnt: a web service to rapidly identify and annotate DNA sequence variations. BMC Bioinform. 11, 471 (2010).
41. Li, W. & Vijg, J. Measuring genome instability in aging - a mini-review. Gerontology 58, 129-138 (2012).
42. Li, F. et al. The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSalpha. Cell 153, 590-600 (2013).
43. Makishima, H. et al. Somatic SETBP1 mutations in myeloid malignancies. Nat. Genet. 45, 942-946 (2013).
44. Yoshida, K. et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478, 64-69 (2011).
45. Molenaar, R. J. et al. Clinical and biological implications of ancestral and nonancestral IDH1 and IDH2 mutations in myeloid neoplasms. Leukemia 29, 2134-2142 (2015).
46. R Foundation for Statistical Computing. R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, 2014).